Indaptus Therapeutics

$5.95 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About Indaptus Therapeutics

Indaptus Therapeutics, Inc, formerly Intec Parent, Inc, offers immunotherapy to cure diseases. The Company is engaged in developing pre-clinical pipeline of therapeutic candidates to produce anti-tumor and anti-viral responses and cure diseases. It designs its approach by targeting specific tumor or viral antigens. Its lead candidate, Decoy20, is in pre-clinical development. Its platform is based on the hypothesis that require anti-tumor immunotherapy to activate both innate and adaptive cellular immunity in both tumors and immune organs. Its approach uses multi-targeted package of bacterial pathogen-associated molecular patterns (PAMPs) in the form of attenuated and killed, intact but non-pathogenic bacteria delivered intravenously. Its intravenous therapeutic candidates target the liver, spleen, and leaky vasculature of tumors, producing immune activation in an immune organ, as well as a common site for primary and metastatic cancer and hepatitis B virus (HBV) infection.

Stock Analysis

last close $6.13
1-mo return -14.4%
3-mo return -38.1%
avg daily vol. 239.33T
52-week high 36.8
52-week low 5.32
market cap. $47M
forward pe -
annual div. -
roe -28.6%
ltg forecast -
dividend yield -
annual rev. $--
inst own. 6.9%
baraka

Subscribe now for daily local and international financial news

Subscribe